Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFX 002

Next Previous
X
Search
Drug Profile

AFX 002

Alternative Names: AFX-002

Latest Information Update: 31 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AffyXell Therapeutics
  • Developer AffyXell Therapeutics; Avacta; Daewoong Pharmaceutical
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Multiple sclerosis

Most Recent Events

  • 27 Feb 2023 Early research in Multiple sclerosis in South Korea (Parenteral), prior to February 2023 (Avacta pipeline, February 2023)
  • 08 Jan 2020 Avacta and Daewoong Pharmaceutical agree to co-develop cell-therapies for Autoimmune disorders and inflammation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top